Lifecore Biomedical (FRA:LDE) Cyclically Adjusted Revenue per Share: €10.29 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LDE Lifecore Biomedical Inc FRA:LDE
51 GF Score
Price €3.74
GF Value €5.49
! 5 Warning Signs
View Full Analysis

What is Lifecore Biomedical Cyclically Adjusted Revenue per Share?

Lifecore Biomedical FRA:LDE +1.08% 51 Cyclically Adjusted Revenue per Share is €10.29 as of Mar. 2026. GuruFocus rates FRA:LDE with a GF Score™ of 51/100 and a GF Value™ of €5.49. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Lifecore Biomedical's adjusted revenue per share for the three months ended in Mar. 2026 was €0.535. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €10.29 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Lifecore Biomedical's average Cyclically Adjusted Revenue Growth Rate was -12.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -9.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -4.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 1.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Lifecore Biomedical was 9.70% per year. The lowest was -9.40% per year. And the median was 4.30% per year.

As of today (2026-08-04), Lifecore Biomedical's current stock price is €3.74. Lifecore Biomedical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €10.29. Lifecore Biomedical's Cyclically Adjusted PS Ratio of today is 0.36.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lifecore Biomedical was 1.06. The lowest was 0.10. And the median was 0.60.


Lifecore Biomedical  (FRA:LDE) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Lifecore Biomedical's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.74/10.29
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lifecore Biomedical was 1.06. The lowest was 0.10. And the median was 0.60.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Lifecore Biomedical Cyclically Adjusted Revenue per Share Related Terms


Lifecore Biomedical Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Lifecore Biomedical's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical Cyclically Adjusted Revenue per Share Chart

Lifecore Biomedical Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.92 16.78 14.80 13.52 11.50

Lifecore Biomedical Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.65 11.50 10.30 0.00 10.29

FRA:LDE vs DERM, ADCT, ANIK: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifecore Biomedical Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Cyclically Adjusted PS Ratio falls into.


FRA:LDE
51GF Score
Lifecore Biomedical Inc FRA:LDE
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lifecore Biomedical Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lifecore Biomedical's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.535/330.2130*330.2130
=0.535

Current CPI (Mar. 2026) = 330.2130.

Lifecore Biomedical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201605 2.321 240.229 3.190
201608 4.291 240.849 5.883
201611 4.560 241.353 6.239
201702 4.633 243.603 6.280
201705 2.116 244.733 2.855
201708 3.520 245.519 4.734
201711 3.743 246.669 5.011
201802 4.204 248.991 5.575
201805 4.261 251.588 5.593
201808 3.853 252.146 5.046
201811 3.948 252.038 5.173
201902 4.701 252.776 6.141
201905 4.673 256.092 6.026
201908 4.280 256.558 5.509
201911 4.426 257.208 5.682
202002 4.808 258.678 6.138
202005 -8.615 256.394 -11.095
202008 3.920 259.918 4.980
202011 3.782 260.229 4.799
202102 1.260 263.014 1.582
202105 -0.723 269.195 -0.887
202108 1.203 273.567 1.452
202111 1.292 277.948 1.535
202202 1.118 283.716 1.301
202205 0.678 292.296 0.766
202208 0.792 296.171 0.883
202211 0.724 297.711 0.803
202302 0.818 300.840 0.898
202305 0.945 304.127 1.026
202308 0.740 307.026 0.796
202311 0.765 307.051 0.823
202402 0.904 310.326 0.962
202405 0.941 314.069 0.989
202408 0.726 314.796 0.762
202411 0.893 315.493 0.935
202502 0.912 319.082 0.944
202505 0.873 321.465 0.897
202509 0.709 324.800 0.721
202512 0.000 324.054 0.000
202603 0.535 330.213 0.535

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €10.29 mean?
Lifecore Biomedical (FRA:LDE) has a Cyclically Adjusted Revenue per Share of €10.29 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Lifecore Biomedical and its competitors.
Is Lifecore Biomedical's Cyclically Adjusted Revenue per Share too high?
Lifecore Biomedical's current Cyclically Adjusted Revenue per Share is €10.29. Overall, Lifecore Biomedical has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's Cyclically Adjusted Revenue per Share compare to DERM and ADCT?
Lifecore Biomedical's Cyclically Adjusted Revenue per Share of €10.29 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Lifecore Biomedical and its competitors. Lifecore Biomedical's current Cyclically Adjusted Revenue per Share is €10.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Lifecore Biomedical (FRA:LDE) has a current Cyclically Adjusted Revenue per Share of €10.29. The stock's GF Value™ is €5.49, compared to a current price of €3.74 — trading 31.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €10.29. Lifecore Biomedical's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Lifecore Biomedical (FRA:LDE), the current Cyclically Adjusted Revenue per Share is €10.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lifecore Biomedical (FRA:LDE) Overvalued in 2026?

Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued. The current stock price of €3.74 is trading 31.9% below its estimated GF Value™ of €5.49.

Key valuation signals for FRA:LDE:

  • Cyclically Adjusted Revenue per Share: €10.29
  • GF Value™: €5.49 vs. price of €3.74 (31.9% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the FRA:LDE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lifecore Biomedical Business Description

Other Exchanges LFCR:USA
Address 3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
51GF Score

Get the complete analysis for FRA:LDE

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.74
Price
€5.49
GF Value